Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000853 | 0.81 | CHRM2 (0.35) | ALOX5CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL5000825 | 0.73 | — | — | |
| SCHEMBL5506416 | 0.70 | AKR1C4 (0.37) | — | |
| SCHEMBL6429689 | 0.69 | CHRM2 (0.45) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL28030332 | 0.67 | TAS2R46 (0.39) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL16221684 | 0.66 | CHRM2 (0.46) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL14750314 | 0.66 | CHRM2 (0.46) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL19962806 | 0.66 | CHRM2 (0.46) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL3672951 | 0.66 | TAS2R46 (0.41) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL3672947 | 0.66 | TAS2R46 (0.41) | CHRM2CHRM1CHRM4CHRM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161306-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1856044-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006087548-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161306-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | ALOX5 2940/4885CHRM2 4830/4885CHRM1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.